<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00916123</url>
  </required_header>
  <id_info>
    <org_study_id>0812010139</org_study_id>
    <nct_id>NCT00916123</nct_id>
  </id_info>
  <brief_title>Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer</brief_title>
  <official_title>A Phase I Trial of Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Anti-prostate-specific Membrane Antigen Monoclonal Antibody in Patients With Metastatic, Castrate-resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effectiveness of the experimental drug, 177Lu-J591&#xD;
      antibody in combination with docetaxel chemotherapy against metastatic, castrate-resistant&#xD;
      prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research is being done because the standard treatments for metastatic prostate cancer&#xD;
      that is growing despite medical or surgical therapies are not curative. Existing treatments,&#xD;
      such as the docetaxel used as part of this study, may work temporarily, but unfortunately the&#xD;
      cancer continues to grow. This test drug, 177Lu-J591, is designed to seek out prostate cancer&#xD;
      cells and deliver a lethal dose of radiation to the areas of cancer, but not to normal areas.&#xD;
      Some of the normal organs (liver, kidney and bone marrow) do receive some radiation dose that&#xD;
      is within the acceptable limits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2009</start_date>
  <completion_date type="Actual">December 2018</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose of fractionated 177Lu-DOTA-J591 administered concurrently with three-weekly docetaxel for the treatment of patients with metastatic, castrate-resistant prostate cancer.</measure>
    <time_frame>4 weeks post last J591 dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the toxicity profile of concurrent docetaxel with fractionated 177Lu-DOTA-J591</measure>
    <time_frame>completion of study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>177Lu-J591 at 20 mCi/dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>177Lu-J591 at 25 mCi/dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>177Lu-J591 at 30 mCi/dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>177Lu-J591 at 35 mCi/dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>177Lu-J591 at 40 mCi/dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75 mg/m2 by intravenous infusion over one hour on day 1 of a 21 day cycle.</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_label>Dose Level 5</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>10 mg per day starting on cycle 1, day 1</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_label>Dose Level 5</arm_group_label>
    <other_name>Meticorten, Sterapred, Sterapred DS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-J591</intervention_name>
    <description>Two infusions of 177Lu-DOTA-J591 at 20 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.</description>
    <arm_group_label>Dose Level 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-J591</intervention_name>
    <description>Two infusions of 177Lu-DOTA-J591 at 25 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.</description>
    <arm_group_label>Dose Level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-J591</intervention_name>
    <description>Two infusions of 177Lu-DOTA-J591 at 30 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.</description>
    <arm_group_label>Dose Level 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-J591</intervention_name>
    <description>Two infusions of 177Lu-DOTA-J591 at 35 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.</description>
    <arm_group_label>Dose Level 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>177Lu-J591</intervention_name>
    <description>Two infusions of 177Lu-DOTA-J591 at 40 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.</description>
    <arm_group_label>Dose Level 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologic diagnosis of prostate adenocarcinoma.&#xD;
&#xD;
          -  Patient must have progressive metastatic prostate cancer despite adequate medical or&#xD;
             surgical castration therapy.&#xD;
&#xD;
          -  Serum testosterone &lt; 50 mg/ml.&#xD;
&#xD;
          -  Patients who have previously received docetaxel must meet BOTH of the the following&#xD;
             criteria:&#xD;
&#xD;
               -  reason for docetaxel discontinuation must NOT have been progression of disease&#xD;
                  while receiving drug (i.e. progression of cancer must have been AFTER docetaxel&#xD;
                  discontinuation) AND&#xD;
&#xD;
               -  All docetaxel-related toxicities must have resolved to &lt; grade 1 (with the&#xD;
                  exception of alopecia) and the pt must be eligible by other criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of red blood cell or platelet transfusions within 4 weeks of treatment.&#xD;
&#xD;
          -  Use of hematopoietic growth factors within 4 weeks of treatment.-Prior cytotoxic&#xD;
             chemotherapy and/or radiation therapy within 4 weeks of treatment.&#xD;
&#xD;
          -  Bone scan demonstrating confluent lesions involving both axial and appendicular&#xD;
             skeleton (&quot;superscan&quot;).&#xD;
&#xD;
          -  Prior radiation therapy encompassing &gt;25% of skeleton.Prior treatment with 89Strontium&#xD;
             or 153Samarium containing compounds (e.g. Metastron®, Quadramet®).&#xD;
&#xD;
          -  Platelet count &lt;150,000/mm3.&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt;2,000/mm3.&#xD;
&#xD;
          -  Hematocrit &lt;30 percent or Hemoglobin &lt; 10 g/dL.&#xD;
&#xD;
          -  Abnormal coagulation profile (PT or INR, PTT) &gt; 1.3 x upper limit of normal (unless on&#xD;
             therapeutic anticoagulation).&#xD;
&#xD;
          -  -Serum creatinine &gt;2.5 mg/dL.&#xD;
&#xD;
          -  AST (SGOT) &gt;2.5x ULN.&#xD;
&#xD;
          -  Bilirubin (total) &gt;1.5x ULN.&#xD;
&#xD;
          -  Serum calcium &gt;11 mg/dL.&#xD;
&#xD;
          -  Active serious infection.&#xD;
&#xD;
          -  Active angina pectoris or New York Heart Association Class III-IV.&#xD;
&#xD;
          -  ECOG Performance Status &gt;2.&#xD;
&#xD;
          -  Life expectancy &lt;6 months.&#xD;
&#xD;
          -  Deep vein thrombosis and/or pulmonary embolus within 1 month of study entry.&#xD;
&#xD;
          -  Other serious illness(es) which might preclude completion of this study or interfere&#xD;
             with determination of causality of any adverse effects experienced in this study.&#xD;
&#xD;
          -  Prior anti-PSMA monoclonal antibody therapy with the exception of ProstaScint®.&#xD;
&#xD;
          -  Prior investigational therapy within 6 weeks of treatment.&#xD;
&#xD;
          -  Known history of HIV.&#xD;
&#xD;
          -  Known history of myelodysplastic syndrome or leukemia&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Tagawa, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Chapel Hill Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Batra JS, Niaz MJ, Whang YE, Sheikh A, Thomas C, Christos P, Vallabhajosula S, Jhanwar YS, Molina AM, Nanus DM, Osborne JR, Bander NH, Tagawa ST. Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177)Lu-J591) for metastatic castration-resistant prostate cancer. Urol Oncol. 2020 Nov;38(11):848.e9-848.e16. doi: 10.1016/j.urolonc.2020.05.028. Epub 2020 Jun 27.</citation>
    <PMID>32600929</PMID>
  </results_reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 5, 2009</study_first_submitted>
  <study_first_submitted_qc>June 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2009</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>castrate-resistant prostate cancer</keyword>
  <keyword>CRPC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

